Incyte (INCY) Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib in Patients with HS streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results from open-label extension period of the Phase 2 trial demonstrate that longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms Data
Board expansion brings significant additional gene therapy and corporate development expertise to AnjariumZURICH, Oct. 18, 2022 /PRNewswire/ Anjarium Biosciences AG ("Anjarium"), a biotech
Dopavision Appoints Mark S Wuttke, Ph D , as Chief Executive Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities- Company recently initiated clinical trial of.